Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases.

Iris M GoldsteinLaila Catalina RoismanShoshana Keren-RosenbergJulia DudnikHovav NechushtanIlan ShelefVered FuchsWaleed KianNir Peled

Published in: Neuro-oncology advances (2020)

Osimertinib 160 mg is feasible and may offer a therapeutic alternative for patients with isolated intracranial progression on osimertinib standard (80 mg) dose. Further studies on CNS osimertinib pharmacokinetics are needed to test this hypothesis.

Keyphrases

small cell lung cancer
brain metastases
epidermal growth factor receptor
advanced non small cell lung cancer
tyrosine kinase
randomized controlled trial
blood brain barrier
open label
wild type